
Vasilis Stavrinides,, Mrcs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7186874/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?. British Journal of Radiology, 2022, 95, 20210321.	1.0	5
2	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.2	13
3	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	1.2	2
4	Magnetic Resonance Imaging–guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies. European Urology Open Science, 2022, 38, 40-43.	0.2	5
5	Image quality assessment for machine learning tasks using meta-reinforcement learning. Medical Image Analysis, 2022, 78, 102427.	7.0	19
6	Orchidopexy for Testicular Torsion: A Systematic Review of Surgical Technique. European Urology Focus, 2021, 7, 1493-1503.	1.6	22
7	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
8	Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. European Radiology, 2021, 31, 1644-1655.	2.3	37
9	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naÃ ⁻ ve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. European Urology, 2021, 79, 20-29.	0.9	13
10	Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and Quality. Urology, 2021, 148, 316-317.	0.5	1
11	Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out. BJU International, 2021, 127, 169-170.	1.3	5
12	Adaptable Image Quality Assessment Using Meta-Reinforcement Learning of Task Amenability. Lecture Notes in Computer Science, 2021, , 191-201.	1.0	4
13	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. Cancers, 2021, 13, 1985.	1.7	10
14	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Letter Journal of Urology, 2021, 205, 1233-1234.	0.2	0
15	Morphological Change Forecasting For Prostate Glands Using Feature-Based Registration And Kernel Density Extrapolation. , 2021, , .		1
16	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter Journal of Urology, 2021, 205, 1526-1528.	0.2	0
17	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. Prostate Cancer and Prostatic Diseases, 2021, 24, 1028-1031.	2.0	10
18	Cellular senescence as a possible link between prostate diseases of the ageing male. Nature Reviews Urology, 2021, 18, 597-610.	1.9	19

#	Article	IF	CITATIONS
19	Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. European Radiology, 2020, 30, 2082-2090.	2.3	20
20	Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443–51. European Urology, 2020, 78, e112-e113.	0.9	0
21	Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging–based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020:78:443–51. European Urology. 2020. 78. e166.	0.9	0
22	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. Scientific Reports, 2020, 10, 17177.	1.6	4
23	Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE. British Journal of Radiology, 2020, 93, 20200819.	1.0	11
24	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. European Urology, 2020, 78, 163-170.	0.9	60
25	Five-year Outcomes of Magnetic Resonance Imaging–based Active Surveillance for Prostate Cancer: A Large Cohort Study. European Urology, 2020, 78, 443-451.	0.9	94
26	Mycobacterial immunotherapy for prostate cancer: where can we go from here?. Nature Reviews Urology, 2020, 17, 189-190.	1.9	2
27	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. Journal of Urology, 2020, 204, 1065-1066.	0.2	0
28	MRI in active surveillance: a critical review. Prostate Cancer and Prostatic Diseases, 2019, 22, 5-15.	2.0	36
29	The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing. Cancers, 2019, 11, 1233.	1.7	31
30	Stroma in normal and cancer wound healing. FEBS Journal, 2019, 286, 2909-2920.	2.2	27
31	Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRlâ€characterized prostates. Prostate, 2018, 78, 1229-1237.	1.2	9
32	Can MRI Replace Biopsy in Men on Surveillance?. Current Clinical Urology, 2018, , 111-119.	0.0	0
33	When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers. Cancer Treatment Reviews, 2017, 58, 14-21.	3.4	12
34	Isolated bilateral simplex ureteric ectopia: Bladder capacity as an indicator of continence outcome. Journal of Pediatric Urology, 2017, 13, 493.e1-493.e9.	0.6	2
35	MP51-12 A TRAINING COURSE FOR THE UROLOGIST IMPROVES THEIR ABILITY TO INTERPRET CLINICALLY SIGNIFICANT PROSTATE CANCER ON MULTIPARAMETRIC MRI. Journal of Urology, 2017, 197, .	0.2	0
36	A Case of Persistent Foot Pain in a Neurofibromatosis Type I Patient. Case Reports in Medicine, 2012, 2012, 1-3.	0.3	2

#	Article	IF	CITATIONS
37	Outcome in surgically treated Rathke's cleft cysts: long-term monitoring needed. European Journal of Endocrinology, 2011, 165, 33-37.	1.9	38